According to forecasts, the bronchopulmonary dysplasia treatment market is expected to be USD 385.6 million in 2023 and USD 700.2 million by 2033.
In the upcoming years, the bronchopulmonary dysplasia market’s dynamics are projected to evolve. Due to a dearth of authorized treatments, new medicines like OHB-607 may capture a sizable portion of the bronchopulmonary dysplasia market. Our knowledge of BPD’s pathophysiology is quickly expanding thanks to exciting new technology developments in the research arena, providing new opportunities for exploring the need for bronchopulmonary dysplasia treatments.
Unlock Key Market Trends: Get Your Sample Report! https://www.futuremarketinsights.com/report-sample#5245502d47422d34333839
More research with well-defined outcomes is required to provide efficient and focused medicines that deliver the best possible care. Existing models are being improved to better replicate pathological processes in afflicted babies to test novel potential pharmaceutical treatments for BPD therapy.
The market in North America is also boosted by modern technology, an increase in public knowledge of illness treatments, and high healthcare spending. Also, a sizable portion of the worldwide market is predicted to belong to Europe. Throughout the projection period, it is expected that Asia Pacific would have quicker growth.
Undiagnosed, unreported instances and lack of knowledge about the condition are the key factors driving the growth of bronchopulmonary dysplasia market.
Key Takeaways
- By 2033, the bronchopulmonary dysplasia treatment market in the United Kingdom is likely to expand, with a CAGR of 5.2%.
- In 2022, the United States developed the bronchopulmonary dysplasia treatment business with a share of 35.6%.
- The bronchopulmonary dysplasia treatment market grew considerably to USD 366 million in 2022.
- The bronchopulmonary dysplasia treatment market expanded with a CAGR of 5.0% between 2018 to 2022.
- By 2033, China’s bronchopulmonary dysplasia treatment market is projected to develop with a CAGR of 9.1%.
- By 2033, India’s bronchopulmonary dysplasia treatment industry is projected to expand with a CAGR of 7.4%.
- Japan’s bronchopulmonary dysplasia treatment industry grew significantly, with a 3.0% share in 2022.
- Australia’s bronchopulmonary dysplasia treatment market is likely to expand with a CAGR of 6.6% by 2033.
- Germany’s bronchopulmonary dysplasia treatment business grew, with a share of 7.8% in 2022
- In 2022, based on the therapy, supplement oxygen therapy dominated the market, with a share of 35.8%.
- In 2022, the hospital segment dominated the market, with a share of 47.5%, based on end users.
Increased Market Demand: Get In-Depth Analysis and Insights with Our Complete Report! https://www.futuremarketinsights.com/reports/bronchopulmonary-dysplasia-treatment-market
Competitors Winning Strategies
Key competitors have utilized tactics including intense research and development, cost-effective and efficient medications, and cooperative alliances to gain control of the worldwide bronchopulmonary dysplasia therapy sector.
Accessibility and well-established healthcare infrastructure are key factors influencing industry expansion. Investments made by major companies in this industry have accelerated market expansion. Airway Therapeutics LLC reported in March 2022 that the Phase 1b randomized study AT-100 (rhSP-D) for prophylactic usage in extremely preterm babies at risk for bronchopulmonary dysplasia had dosed its first patient.
Key Players
- Airway Therapeutics LLC
- Chiesi Farmaceutici SpA
- Insmed Incorporated
- MediPost Co. Ltd.
- Meridian Biotech Co. Ltd
- Syntrix Biosystems Inc.
- Martindale Pharmaceuticals
- Takeda
- Mallinckrodt
- AdventHealth
Key Segments
By Drug Type:
- Bronchodilators
- Diuretics
- Antibiotics
- Steroids
- Immunomodulators
- Surfactant Homeostasis
By Therapy Type:
- Nitric Oxide Therapy
- Protein replacement therapy
- Stem Cell Therapy
- Supplemental Oxygen
By End User:
- Hospitals
- Nursing Homes
- Critical Care Centers
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Unlock Key Insights into Healthcare Market Growth! https://www.futuremarketinsights.com/industry-analysis/therapy-area
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
